Nitric oxide (NO), synthesized from L-arginine by a family of constitutive and inducible NO synthases (cNOS and iNOS), is a small, diffusible, highly reactive molecule with dichotomous biological functions, such as blood vessel dilatation, neurotransmission, modulation of the hair cycle, and penile erections 1 . NO can also be generated from synthetic NO-releasing compounds, such as nitrate, furoxan, hydroxyguanidine, S-nitrosothiol, diazeniumdiolate, and others 2 . Higher concentrations of NO can promote the apoptosis of many types of cells, while lower concentrations of NO usually protect cells, such as hepatocytes, from inflammation-mediated apoptosis 3 . Several mechanisms have been proposed to explain the anti-apoptosis effects of NO, including increased cGMP production, inhibition of caspase activation as well as prevention of mitochondrial permeability transition that leads to the release of cytochrome C into the cytosol 4 .
Increasing scientific evidence indicates that NO deficiency is implicated in many physiological and pathological processes within the mammalian body. This fact provides a plausible biologic basis for the application of NO replacement therapy in clinic.
However, the diverse bioactivities of NO limit its clinical application. New types of NO-releasing compounds/drug hybrids need to be developed for obtaining tissue-specific NO-related function.
Oleanolic acid (OA) is a triterpenoid compound, widely found in natural plants 5 . Systemic treatment with the purified OA leads predominately to the distribution and metabolism of OA in the liver. OA has been shown to protect rodent liver from CCl 4 and many other toxicant-induced hepatotoxicity and chronic cirrhosis 6 . Importantly, OA has been clinically used as a safe nonprescription drug for treatment of hepatitis in China for more than 20 years 7 , although its therapeutic efficacy is limited. The therapeutic effect, the property of liver-specific metabolism, and wide availability make it to be an ideal base for the design of new NO-leasing compounds for the production of NO specifically in the liver. The combination of NO and OA probably provides synergic protection of hepatocytes from inflammationand toxicant-mediated liver damage.
In the present studies, 106 novel NO-releasing derivatives of OA were synthesized by connecting organic nitrates to the OA-28-COOH through varying lengths of linkers. The various linkers containing anti-oxygen functionalities, such as ferulic acid, p-hydroxyl cinnamic acid and vanillic acid 8 were designed to increase the ability of these objective compounds to scavenge free radicals. The bioactivities of all derivatives of OA were evaluated. Several compounds were found to inhibit anti-Fas mediated hepatocyte apoptosis and their anti-apoptotic effects were dose-dependent. One of the compounds, 8b, inhibited hepatocyte apoptosis at lower nanomolar level. The development of new NO-releasing derivatives of OA may aid in the design of NO-based new medicine for the intervention of human inflammatory liver diseases.
The synthetic routes of very important intermediates (2a-2g, 6a-6b) are outlined in scheme 1. Ferulic acid (1a) or p-hydroxyl cinnamic acid (1b) was first treated with 2 to 6 carbons of dibromoalkanes in the presence of Et 3 N and acetone at 50 to generate compounds 2a-2g in 60-73% yields. In a similar way, compounds 6a and 6b were obtained in 61-65% yields by treatment of vanillic acid (5) The synthetic routes of OA-nitrate conjugates (8a-8g, 9a-9g and 11a-11b, 12a-12b) are summarized in schemes 2 and 3. Several strategies were attempted to esterify OA-28-COOH directly with hydroxyl compounds, but failed, perhaps because of the large steric hindrance and weak acidity of OA-28-COOH. Alternatively, OA was first treated with trifluoroacetic anhydride to form a mixed anhydride in a quantitative yield after stirring at room temperature for 10 min. The resulting mixed anhydride was then reacted with hydroxyl compounds (2a-2g or 6a-6b) in toluene to afford 3-O-trifluoroacetyl OA esters (7a-7g and 10a-10b) in good yields (70-78%), respectively 9, 10 . Compounds 7a-7g and 10a-10b were further converted to the corresponding nitrates 8a-8g and 11a-11b respectively with AgNO 3 in THF/CH 3 CN. Compounds 9a-9g and 12a-12b were prepared by the hydrolysis of 8a-8g and 11a-11b with diluted KHCO 3 to remove trifluoroacetyl group at C-3-OH without affecting other ester bonds. The resulting products were purified by column chromatography and their structures were established by IR, 1 Compounds 8a-8g, 9a-9g, 11a, 11b and 12a,12b as well as controls, OA and NCX-1000 were evaluated for their protective effects on anti-Fas mediated apoptosis in HepG2 determined by LDH assay 12 . As shown in Fig. 1 , treatment with different concentrations of OA failed to protect the HepG2 cells from anti-Fas induced apoptosis as there was no significant difference in the percentage of survived HepG2 cells between the presence and absence of different concentrations of OA. Treatment with NCX-100, a NO-releasing derivative of ursodeoxycholic acid (UDCA) generated by adding an ONO 2 moiety through an antioxidant spacer, showed moderate protective effects and NCX-100 at 10 -6 M protected 33.4% of HepG2 cells from anti-Fas induced apoptosis, consistent with previous report 3 . Furthermore, five of the tested compounds displayed great protective effects, which were 10-1000 folds stronger than that of NCX-1000. The lowest concentration that significantly inhibited anti-Fas induced HepG2 cell apoptosis was 10 -10 for 8b, 10 -9 for 8c, 10 -8 for 8f or 10 -7 for 8d and 8g, respectively. A similar pattern of protective effects was observed when using the p53 -/-Hep3b cells, indicating that the protective effects of these NO-releasing derivatives of OA were independent of p53. Given that Fas/FasL-mediated hepatocyte apoptosis was involved many inflammatory-and toxicant-mediated liver diseases the potent anti-apoptotic effect of NO-releasing derivatives of OA suggests that these compounds may be potential for the treatment of inflammatory diseases in clinic. /well were plated in triplicate in 96-well plates in 4% FCS and 2 μg/ml Phenol-red free DMEM. The cells were treated with anti-Fas (50 ng/ml for CH-11 or 1.5 μg/ml for DX2) in the presence or absence of indicated concentrations of OA, NCX-1000, or NO-releasing derivatives of OA at 37°C 5% CO2 for 18 h. Unmanipulated cells or the cells treated with 1% triton X-100 were used as negative or positive controls for cytotoxicity. Their supernatants were harvested and their contained LDH activities were measured by LDH assays using the LDH cytotoxicity detection kit ( Analysis of NO production by these compounds revealed that the compounds 8b and 8c produced about 0.01μg/ml determined by in vitro Griess reaction of 300 minutes period. This low dose of NO production was consistent with the notion that low dose of NO protects cells from inflammation-mediated apoptosis. Notably, some compounds that produced higher dose of NO in vitro showed direct cytotoxicity on human liver cancer cells (unpublished observations). In addition, the compound 8b was selected for testing whether treatment with 8b could inhibit CCl 4 induced hepatic fibrosis and liver damage in rats. Interestingly, oral treatment with 8b at 128 mg.kg -1 significantly inhibited CCl 4 -induced hepatic fibrosis and liver damage in the rats (data not shown). Collectively, NO-releasing derivatives of OA, which produced low concentrations of NO, protected human hepatocytes from anti-Fas mediated apoptosis and inhabited CCl 4 -induced liver damage in rat.
Analysis of structure activity relationships suggests that the A-ring of OA may be a good target for further modification as the compounds 8b, 8c, 8d, 8f and 8g whose C-3-OH of A-ring was connected with trifluoroacetyl, showed potent anti-apoptotic activities, while the compounds 9b, 9c, 9d, 9f and 9g with corresponding free C-3-OH were inactive. Secondly, the length of the linkers connecting to ferulic acid or p-hydroxyl cinnamic acid is crucial for their bioactivities. The 8b with a 3-carbon long linker had 10-100 folds more potent anti-apoptotic activity than 8c or 8d respectively, while 8a was inactive. Similarly, the compounds 8e and 8f, but not 8g, had anti-apoptotic activity. Apparently, a 3-carbon long of linker was optimal while longer linkers were accompanied by decreased bioactivities. Furthermore, the potent anti-apoptotic activities were governed by appropriate anti-oxygen reagent, like ferulic acid, at the C-28 of OA esters as compounds 8b and 8c showed higher anti-apoptotic activities than the corresponding compounds 8f, 8g and 11b, even if they had the same length of carbon chain. Finally, these OA-nitrate conjugates at less than 10 -6 M, but not OA, inhibited anti-Fas mediated HepG2 cell apoptosis in our experimental system, suggesting that the NO-releasing moieties may be responsible for the inhibitory activities of these derivatives of OA.
A series of OA-nitrate conjugates were synthesized and their biological functions were evaluated. Within the series of compounds, five of them showed to inhibit anti-Fas mediated hepatocyte apoptosis in vitro and their anti-apoptotic effects were dose-dependent. Notably, the compound 8b was the most potent inhibitor and protected hepatocytes from anti-Fas mediated apoptosis at a lower nanomolar level. The preliminary SAR analysis of these compounds revealed that connection of the A-ring of OA with an optimal length of linker, and with an anti-oxygen reagent at the C-28 of OA esters were crucial for their anti-apoptotic activities. Together, these findings provide a new framework for the rational design of NO-based medicine for the intervention of human inflammatory liver diseases in clinic.
